Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.41 |
| ▸ | CTSL | P07711 | 14/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624315 | 0.93 | CTSK (0.40) | CTSKCTSLCTSSCTSBMAPT | |
| SCHEMBL13624289 | 0.90 | CTSK (0.48) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624431 | 0.87 | CTSL (0.48) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624316 | 0.87 | CTSK (0.39) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624310 | 0.85 | CTSK (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624317 | 0.84 | SMN1; SMN2 (0.42) | CTSKCTSLCTSSCTSBLMNA | |
| SCHEMBL13624391 | 0.83 | CTSK (0.40) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624430 | 0.83 | CTSK (0.40) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624312 | 0.82 | CTSK (0.41) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624340 | 0.82 | CTSS (0.45) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSK 15/4885CTSL 24/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.